Loading stock dataβ¦
$11.38-0.53 (-4.49%)
Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. in the Healthcare sector is trading at $11.38 with a market capitalization of $1.7B. Wall Street consensus targets $23.11 (18 analysts), implying a +103.0% move over the next 12 months. The stock is currently near its 52-week low of $7.95, remaining 12.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.66Mβ | $15.05Mβ | $23.02Mβ | $13.78Mβ | $14.24M |
| Gross Profit | β | β | β | β | β |
| Operating Income | -$112.76Mβ | -$100.53Mβ | -$98.71Mβ | -$111.48Mβ | -$110.00M |
| Net Income | -$106.63Mβ | -$96.23Mβ | -$95.79Mβ | -$101.32M | -$101.25M |
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeat...